Hydrogen gas (H2) delivered by intraperitoneal injection alleviated methionine- and choline-deficient diet-induced metabolic dysfunction–associated steatotic liver disease in mice via inhibiting GSDMD- and GSDME-mediated pyroptosis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis shows hydrogen gas improves metabolic dysfunction-associated steatotic liver disease, indicating a potential new therapy.

Hydrogen gas treatment significantly reduced signs of hepatic steatosis and fibrosis in MCD diet-fed mice, ensuring liver health.
Key metrics revealed decreased serum ALT and AST levels, indicating improved liver function following H2 administration.
Assessment utilized a methionine- and choline-deficient diet model, with hydrogen gas administered via intraperitoneal injection over two weeks.
These findings suggest hydrogen gas therapy may provide a novel approach to managing MASLD and warrant further exploration.

Chen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows hydrogen gas improves metabolic dysfunction-associated steatotic liver disease, indicating a potential new therapy.